Buccal vs. Oral Delivery: The Science Behind Absorption and Bioavailability

We tend to assume that once we swallow a medication, the job is done. But in reality, that is only the beginning. The path a drug takes through the body can change how fast it works, how much of it is absorbed, and whether it works at all.

Between buccal administration and the oral route, which one do you think is faster? Or more effective?

In this article, we’ll explain what your supplements go through in each case, so you can understand the real difference.

Before We Compare: One Key Concept

The landscape of medicine has shifted from simple "pill-swallowing" to sophisticated delivery systems designed to outsmart our own biology. At the heart of this evolution is the concept of bioavailability: the actual fraction of a drug that reaches your bloodstream in an active form. While swallowing a pill (the oral route) is the most familiar method, it often means the drug is partially broken down in the liver before it can circulate, a process known as first-pass metabolism.

Pharmacokinetic Mechanisms of Buccal vs. Oral Routes

The differences between buccal and oral drug administration are primarily explained by how each route influences the core pharmacokinetic processes of absorption, metabolism, and systemic availability.

With oral administration, a drug is swallowed and absorbed mainly in the small intestine, after which it enters the portal circulation and is transported to the liver before reaching systemic circulation [1,3]. During this first pass through the liver, a variable proportion of the drug may be metabolized, sometimes extensively, reducing the amount of active compound that ultimately becomes available in the bloodstream [1]. This phenomenon, known as first-pass metabolism, is a key determinant of oral bioavailability and can lead to significant interindividual variability depending on liver enzyme activity and gastrointestinal factors [1,3].

In contrast, buccal and sublingual administration involve absorption through the oral mucosa, a highly vascularized tissue that allows drugs to diffuse directly into the systemic circulation via the venous drainage of the mouth [2,4]. Because this pathway largely bypasses the gastrointestinal tract and initial hepatic metabolism, a greater fraction of the administered dose may remain unchanged when it reaches circulation [2,4,5]. This difference is particularly relevant for drugs that undergo extensive hepatic metabolism when taken orally.

The rate of absorption also differs between these routes. The oral mucosa, especially the sublingual region, is relatively thin and well perfused, which can enable rapid drug uptake and earlier onset of action compared to the oral route [4,7]. In contrast, oral absorption depends on additional steps, including drug dissolution, gastric emptying, and intestinal transit, all of which can delay and introduce variability in drug absorption [1,6].

However, these advantages are balanced by physiological limitations. The surface area available for buccal absorption is relatively small compared to the gastrointestinal tract, and the permeability of the mucosa restricts the types of drugs that can be effectively delivered this way [2,5]. As a result, buccal administration is typically more suitable for potent compounds requiring lower doses, whereas oral delivery remains more practical for drugs that require larger amounts or sustained release over time [1,6].

Together, these mechanisms explain why the route of administration can significantly influence both the onset and extent of drug exposure, and why buccal delivery is often selected when rapid action or avoidance of first-pass metabolism is clinically important.

Key Differences Between Buccal and Oral Formulations

Advantages of the Buccal Route

Buccal and sublingual delivery can offer clear pharmacokinetic advantages compared to swallowing a drug. As a result of bypassing first-pass metabolism, drugs can enter systemic circulation directly, bypassing the gastrointestinal tract and initial liver metabolism [2,4,5]. This can significantly improve bioavailability for drugs that are otherwise extensively metabolised.

This is well illustrated with certain drugs. Nitroglycerin, for example, has extremely low bioavailability when swallowed due to extensive first-pass metabolism, whereas sublingual administration allows a much greater fraction of the drug to reach circulation [7]. Similarly, buprenorphine shows markedly improved systemic availability when given sublingually compared to oral administration [8].

Transmucosal delivery can also provide rapid absorption. Sublingual fentanyl reaches detectable plasma levels within minutes and achieves high bioavailability, supporting its use in acute pain settings [9].

Beyond pharmacokinetics, this route is practical. It is non-invasive, does not require water, and is useful for patients who have difficulty swallowing [2,4–6]. Because of the rich vascular supply of the oral mucosa, onset is generally faster than with standard oral administration [4,7].

In practice, this can mean the difference between a drug working in minutes versus not reaching effective levels at all.

Limitations of the Buccal Route

The main limits are the small surface area, the need to keep the dosage form in place, and the fact that only small doses are usually practical [2,4,5]. Taste, local irritation (if it’s not well formulated), and accidental swallowing can also reduce effectiveness [2,5]. For those reasons, buccal delivery is not suitable for many drugs, especially larger doses or products that need very precise administration [2,5].

These limitations are not just theoretical; they directly determine which drugs can realistically be formulated for buccal delivery.

This is why it is not a good idea to open an oral capsule and assume the powder will work the same way under the tongue or in the cheek. Oral formulations are usually designed to be swallowed, absorbed in the gastrointestinal tract, and sometimes processed through first-pass metabolism [1,3]. Unless the product was specifically made for buccal delivery, changing the route can reduce effectiveness rather than improve it. This applies across different dosage forms. Medications should be used according to their intended route of administration.

The Route Is Not a Detail. It’s the Mechanism.

Buccal (including sublingual) drug delivery is not just an alternative to swallowing; it represents a fundamentally different pharmacokinetic pathway. By bypassing the gastrointestinal tract and initial hepatic metabolism, it can increase the fraction of the drug that reaches systemic circulation and accelerate the onset of compounds affected by first-pass metabolism [1,2,4,5]. This is why certain drugs, such as nitroglycerin or buprenorphine, are specifically formulated for transmucosal delivery rather than oral administration [7,8].

At the same time, this advantage is conditional. Buccal delivery only works when the drug and its formulation are suited for absorption through the oral mucosa [2,4,5]. The limited surface area, permeability constraints, and the need for proper administration technique mean that this route is generally restricted to potent, low-dose compounds [2,5]. In many cases, oral administration remains entirely adequate, and its simplicity makes it the more practical choice.

Ultimately, the route of administration should be considered part of the drug’s mechanism, not a secondary decision. A drug that performs well when swallowed does not benefit from being repositioned as buccal, and one that fails orally cannot be assumed to work unless it is specifically designed for transmucosal delivery [1,2,5]. There are only a limited number of compounds that can be formulated for both oral and buccal administration, typically requiring specific delivery systems to achieve consistent absorption.

Understanding this distinction is what allows for more precise use of existing therapies and more intentional development of new ones. In pharmacology, the route is not just how a drug enters the body; it defines what the drug becomes once it’s there.

At Troscriptions, buccal troches are designed specifically for transmucosal absorption, allowing compounds to be delivered through the oral mucosa rather than relying entirely on digestion. This approach reflects a broader shift toward delivery systems that align more closely with how the body absorbs and processes compounds.

References

1. Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2018). Goodman & Gilman’s the pharmacological basis of therapeutics (13th ed.). McGraw-Hill.

2. Rathbone, M. J., & Drummond, B. K. (1994). Oral mucosal drug delivery. Marcel Dekker.

3. Rang, H. P., Ritter, J. M., Flower, R. J., & Henderson, G. (2020). Rang & Dale’s pharmacology (9th ed.). Elsevier.

4. Shojaei, A. H. (1998). Buccal mucosa as a route for systemic drug delivery: A review. Journal of Pharmacy & Pharmaceutical Sciences, 1(1), 15–30.

5. Pather, S. I., Rathbone, M. J., Şenel, S., & Choonara, Y. E. (2008). Current status and future trends in buccal drug delivery systems. Expert Opinion on Drug Delivery, 5(5), 531–542.

6. Aulton, M. E., & Taylor, K. M. G. (2018). Aulton’s pharmaceutics: The design and manufacture of medicines (5th ed.). Elsevier.

7. Klabunde, R. E. (2012). Cardiovascular physiology concepts (2nd ed.). Lippincott Williams & Wilkins.

8. Mendelson, J., Upton, R. A., Everhart, E. T., Jacob, P., & Jones, R. T. (1997). Bioavailability of sublingual buprenorphine. Journal of Clinical Pharmacology, 37(1), 31–37.

9. Darwish, M., Tempero, K., Jiang, J. G., & Simonson, P. G. (2008). Relative Bioavailability of Fentanyl Following Various Dosing Regimens of Fentanyl Buccal Tablet in Healthy Japanese Volunteers. Archives of drug information, 1(2), 56–62.